menu
    • menu
    [{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sacituzumab Tirumotecan","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sacituzumab Tirumotecan","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sacituzumab Tirumotecan","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sacituzumab Tirumotecan","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Sichuan Kelun-Biotech Biopharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sichuan Kelun-Biotech Biopharmaceutical

    Menu

    Sichuan Kelun-Biotech Biopharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            VMX
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Breakthrough Designation to Sacituzumab for Advanced NSCLC with EGFR Mutations

                            Details : SKB264 (sacituzumab tirumotecan) is a TROP-2 targeting ADC, being investiated in adult with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer.

                            Brand Name : SKB264

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 03, 2024

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            VMX
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kelun-Biotech's Sacituzumab Tirumotecan Approved in China for Advanced TNBC

                            Details : Sac-TMT (sacituzumab tirumotecan) is a TROP2-directed antibody–drug conjugate which is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC.

                            Brand Name : Sac-TMT

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 27, 2024

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            VMX
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kelun-Biotech’s SKB264 NDA Accepted for Advanced EGFR-Mutant NSCLC

                            Details : SKB264 (sacituzumab tirumotecan) is a TROP-2 targeting ADC, being investiated in adult with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer.

                            Brand Name : SKB264

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 31, 2024

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            VMX
                            Not Confirmed

                            Sichuan Kelun-Biotech Biopharmaceutical

                            China arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kelun-Biotech's TROP2-ADC SKB264 NDA Accepted for Advanced NSCLC

                            Details : SKB264 (sacituzumab tirumotecan) is being evaluated in late-stage clinical trial studies with locally advanced or metastatic epidermal growth factor receptor-mutant non-small cell lung cancer.

                            Brand Name : SKB264

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 20, 2024

                            Lead Product(s) : Sacituzumab Tirumotecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth